Investigational Site Number : 6300001

San Juan 00981

0 studies enrolling now · 9 studies all time

What they study most

Diphtheria Immunisation, Haemophilus Influenzae Type b Immunisation, Healthy Volunteers, Hepatitis B Immunisation, Human Metapneumovirus, Influenza Immunization, Measles Immunisation, Meningococcal Immunisation, Meningococcal Immunisation (Healthy Volunteers), Meningococcal Infection (Healthy Volunteers), Mumps Immunisation, Pertussis Immunisation

Studies at this site

• Study of a Respiratory Syncytial Virus Candidate Encapsulated in a Lipid Nanoparticle Based Formulation in Adults Aged 18 to 50 Years and 60 Years and Older — Completed
• Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate — Completed
• Study on a Live-attenuated Respiratory Syncytial Virus Vaccine for Assessment of Safety, Transmissibility, and Genetic Stability of the Vaccine Virus Among Close Contacts in Infants and Toddlers 6 to < 24 Months of Age in Puerto Rico (USA) — Completed
• Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents — Completed
• Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants — Stopped early
• Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4) — Completed
• Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine in Older Adults Who Received a Primary Vaccination (3 or More Years Earlier) in Study MET49 — Completed
• Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants — Completed
• Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older — Completed